Nanobiotix (NASDAQ:NBTX) Trading 12.5% Higher – Should You Buy?

Nanobiotix S.A. – Sponsored ADR (NASDAQ:NBTX) traded up 12.5% during trading on Wednesday . The stock traded as high as $38.75 and last traded at $39.1010. 20,305 shares changed hands during trading, a decline of 63% from the average session volume of 54,438 shares. The stock had previously closed at $34.77.

Wall Street Analysts Forecast Growth

Several research analysts have recently commented on the company. UBS Group lifted their price target on Nanobiotix from $3.50 to $30.00 and gave the stock a “neutral” rating in a report on Friday, May 1st. Weiss Ratings reiterated a “sell (d-)” rating on shares of Nanobiotix in a report on Tuesday, April 21st. TD Cowen restated a “buy” rating on shares of Nanobiotix in a report on Thursday, March 12th. Finally, Guggenheim boosted their price objective on shares of Nanobiotix from $26.00 to $36.00 and gave the company a “buy” rating in a report on Thursday, April 2nd. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $26.67.

Nanobiotix Price Performance

The firm’s fifty day moving average is $31.89 and its 200-day moving average is $25.30.

Nanobiotix (NASDAQ:NBTX) last issued its quarterly earnings data on Sunday, February 15th. The company reported ($0.23) earnings per share (EPS) for the quarter. The company had revenue of $3.42 million for the quarter. As a group, equities analysts predict that Nanobiotix S.A. – Sponsored ADR will post 0.53 earnings per share for the current year.

Institutional Trading of Nanobiotix

A number of institutional investors and hedge funds have recently bought and sold shares of NBTX. Millennium Management LLC purchased a new stake in Nanobiotix during the fourth quarter worth about $390,000. Royal Bank of Canada increased its stake in Nanobiotix by 2,000.0% during the fourth quarter. Royal Bank of Canada now owns 2,625 shares of the company’s stock worth $61,000 after purchasing an additional 2,500 shares during the period. Marshall Wace LLP purchased a new stake in Nanobiotix during the fourth quarter worth about $220,000. Finally, Optiver Holding B.V. purchased a new stake in Nanobiotix during the third quarter worth about $101,000. 38.81% of the stock is currently owned by hedge funds and other institutional investors.

Nanobiotix Company Profile

Nanobiotix is a clinical-stage biotechnology company headquartered in Paris, France, specializing in the development of novel nanopharmaceuticals to improve cancer treatment. The company’s lead product, NBTXR3, is a first-in-class radioenhancer composed of hafnium oxide nanoparticles designed to amplify the effect of radiotherapy on tumor cells while sparing surrounding healthy tissue. Nanobiotix has established clinical programs across multiple cancer indications, including soft tissue sarcoma, head and neck cancer, and hepatocellular carcinoma.

Since its inception, Nanobiotix has advanced NBTXR3 through pivotal trials and secured CE Mark approval in Europe for the treatment of soft tissue sarcoma.